Want to see TSE:DRUG full AI Analyst Report?
DRUG Stock Chart & Stats
C$101.61
C$1.49(1.49%)
At close: 4:00 PM EDT
C$101.61
C$1.49(1.49%)
Day’s Range― - ―
52-Week RangeC$55.22 - C$170.00
Previous CloseN/A
Volume1.16K
Average Volume (3M)612.00
Market Cap
C$889.28M
Enterprise ValueC$473.17
Total Cash (Recent Filing)C$308.33M
Total Debt (Recent Filing)C$65.70K
Price to Earnings (P/E)―
Beta23.55
Next Earnings
Dec 17, 2026EPS Estimate
-1.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.76
Shares Outstanding9,864,061
10 Day Avg. Volume608
30 Day Avg. Volume612
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)7.08
Price to Sales (P/S)0.00
P/FCF Ratio-66.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$200.62Price Target Upside97.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-6.43
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Extremely Low LeverageExtremely low debt reduces refinancing pressure and fixed financial obligations while the company remains pre-revenue. This gives management greater flexibility to direct capital toward clinical development and limits the balance-sheet risk that can amplify operating losses.
Expanded Equity Funding BaseThe much larger equity base indicates improved funding flexibility and a potentially longer operating runway for advancing the pipeline. Although it does not solve profitability, stronger capitalization can support continued development without relying immediately on high-cost debt.
Proprietary Neuropsychiatric PipelineA focused pipeline of proprietary candidates gives Bright Minds a defined platform around serotonin receptors and several neurological indications. Progress across multiple programs could create partnering or licensing opportunities and diversify development value over time.
Bears Say
No Commercial RevenueThe absence of revenue confirms that the company has not yet established a commercial product base or internally funded operating model. Until a candidate is approved or partnered successfully, continued development depends on financing and potential transactional income.
Widening Operating LossesMaterially widening losses show that spending is increasing faster than any current revenue contribution, leaving no earnings base to absorb development costs. Persistent negative operating results can erode the equity base and increase the capital required before programs reach commercialization.
Accelerating Cash BurnThe sharp increase in operating cash burn indicates rising spending intensity and weak near-term self-funding capacity. Even with low debt and a larger equity base, sustained negative cash flow may require additional capital before clinical programs generate partnering proceeds or product revenue.
Bright Minds Biosciences News
DRUG FAQ
What was Bright Minds Biosciences’s price range in the past 12 months?
Bright Minds Biosciences lowest stock price was C$55.22 and its highest was C$170.00 in the past 12 months.
What is Bright Minds Biosciences’s market cap?
Bright Minds Biosciences’s market cap is C$889.28M.
When is Bright Minds Biosciences’s upcoming earnings report date?
Bright Minds Biosciences’s upcoming earnings report date is Dec 17, 2026 which is in 101 days.
How were Bright Minds Biosciences’s earnings last quarter?
Bright Minds Biosciences released its earnings results on Aug 14, 2026. The company reported -C$0.239 earnings per share for the quarter, beating the consensus estimate of -C$1.692 by C$1.453.
Is Bright Minds Biosciences overvalued?
According to Wall Street analysts Bright Minds Biosciences’s price is currently Undervalued.
Does Bright Minds Biosciences pay dividends?
Bright Minds Biosciences does not currently pay dividends.
What is Bright Minds Biosciences’s EPS estimate?
Bright Minds Biosciences’s EPS estimate is -1.47.
How many shares outstanding does Bright Minds Biosciences have?
Bright Minds Biosciences has 9,864,061 shares outstanding.
What happened to Bright Minds Biosciences’s price movement after its last earnings report?
Bright Minds Biosciences reported an EPS of -C$0.239 in its last earnings report, beating expectations of -C$1.692. Following the earnings report the stock price went up 0.745%.
Which hedge fund is a major shareholder of Bright Minds Biosciences?
Currently, no hedge funds are holding shares in TSE:DRUG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bright Minds Biosciences
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
DRUG Stock 12 Month Forecast
Average Price Target
C$200.62
▲(97.44% Upside)